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Abstract 
 
Although the DSM-5 has suggested the two new categories of Persistent Depressive Disorders (PDD) and 
Other Specified Depressive Disorders (OSDD), no study so far has applied the DSM-5 criteria throughout the 
range of depressive disorders. The aims of the present study were to 1) establish the lifetime prevalence of 
specific depressive disorders according to the new DSM-5 definitions in a community sample, and 2) 
determine their clinical relevance in terms of socio-demographic characteristics, comorbidity, course and 
treatment patterns. The semi-structured Diagnostic Interview for Genetic Studies was administered by 
masters-level psychologists to a random sample of an urban area (n=3’720). The lifetime prevalence was 
15.2% for PDD with persistent major depressive episode (MDE), 3.3% for PDD with pure dysthymia, 28.2% 
for Major Depressive Disorder (MDD) and 9.1% for OSDD. Subjects with PDD with persistent MDE were the 
most severely affected, followed by those with recurrent MDD, single episode MDD, PDD with pure dysthymia 
and OSDD and finally those without depressive disorders. Our data provide further evidence for the clinical 
significance of mild depressive disorders (OSDD), but cast doubt on the pertinence of lumping together PDD 
with persistent MDE and the former DSM-IV dysthymic disorder within the new PDD category. 
 
 
Key words: major depression; persistent depression; subthreshold depression; prevalence; course; 
comorbidity; treatment.  
1. Introduction  
Depressive syndromes are frequently disabling mood disorders which have a large economical impact 
(Cuijpers and Smit, 2008) because they lead to significant psychosocial impairment and even excess mortality 
(Cuijpers et al., 2013; Lasserre et al., 2016). The Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV), provided algorithmic definitions for Major Depressive Disorder (MDD) and Dysthymic 
disorder, whereas the category of Depressive disorders not otherwise specified (NOS) grouped together a 
series of syndromes which failed to meet the DSM-IV criteria for MDD or Dysthymic disorder. The major 
changes of DSM-5 regarding the definitions of depressive disorders were the introduction of the new 
categories of 1) persistent depressive disorder (PDD), 2) premenstrual dysphoric disorder, which was part of 
Depressive disorders NOS in the DSM-IV, 3) disruptive mood dysregulation disorder for children, and 4) other 
specified depressive disorders (OSDD). Moreover, the rigid bereavement exclusion for major depressive 
episodes (MDE) was replaced by a detailed footnote, which should help clinicians to distinguish this type of 
episode from grief.  
 
The new category of PDD includes both DSM-IV defined chronic MDD and Dysthymic disorder and provides 
several specifiers that define the combinations between these two conditions: 1) PDD with persistent MDE, 
whereby the full criteria for MDE have been met throughout a 2-year period; 2) PDD with intermittent MDE, 
whereby the criteria for one or more MDE have been met during a 2-year period of dysthymia but the 
symptoms did not reach the diagnostic threshold of MDE during at least 8 weeks; and 3) PDD with pure 
dysthymic syndrome with no MDE occurring during a 2-year period. However, up to this day there are hardly 
studies that compared the clinical characteristics and consequences of these chronic forms of depression 
amongst each other and with those of MDD. 
 
In addition, within the new category of OSDD the DSM-5 proposes operationalized definitions for three 
syndromes that occur below the diagnostic threshold of MDE. Two of them, "Recurrent brief depression” 
(depressed mood and at least four other symptoms of MDE for 2-13 days at least once a month for a 
minimum of 12 consecutive months) and "Depressive episode with insufficient symptoms”, (depressed mood 
and 1-3 of the other eight symptoms of MDE that persist for at least 2 weeks, associated with clinically 
significant distress or impairment), correspond to those previously defined in the DSM-IV NOS category, 
whereas “Short-duration depressive episode (4-13 days)" (depressed mood and at least four other symptoms 
of MDE, associated with clinically significant distress or impairment) is newly introduced. These subthreshold 
depressive syndromes have gained increasing interest in the last two decades (Angst et al., 2014a; Angst et 
al., 2007; Angst and Merikangas, 1997; Angst et al., 2000; Howland et al., 2008; Judd et al., 2002; Kruijshaar 
et al., 2003; Meeks et al., 2011; Rodriguez et al., 2012). However, previous research has used a wide variety 
of definitions in order to establish the clinical relevance of these syndromes, which may partially account for 
differing findings across studies (Rodriguez et al., 2012). Among these syndromes “Minor depression” was the 
most frequently studied condition. Community studies have reported prevalence estimates for this condition 
ranging from 2.8 (Lamers et al., 2010) to 6.1% (Cuijpers et al., 2004) and even up to 9.9% in the Zurich cohort 
assessed over a period of 15 years (Angst and Merikangas, 1997). Previous research has also provided 
evidence regarding the clinical significance of these former subthreshold conditions, showing them to be 
almost as impairing as MDD or Dysthymic disorder (Angst et al., 2014a; Cuijpers and Smit, 2008; Howland et 
al., 2008; Judd et al., 2002; Kruijshaar et al., 2003; Meeks et al., 2011; Rodriguez et al., 2012).  
 
Although previous studies using various diagnostic criteria have provided evidence for the clinical significance 
of depressive syndromes occurring below the threshold of MDD and dysthymia, there is so far no study that 
strictly applied DSM-5 criteria throughout the range of depressive disorders including the newly defined 
categories of PDD and OSDD. Accordingly, the aims of the present study were 1) to establish the lifetime 
prevalence of specific depressive disorders according to the new DSM-5 definitions in a randomly recruited 
community sample, and 2) to determine their clinical relevance in terms of socio-demographic characteristics 
as well as comorbidity, course and treatment patterns by comparing subjects across depressive disorders and 
with subjects with no history of depressive disorders. 
 
2. Material and methods section 
2.1. Sample 
The sample of the present paper stemmed from the PsyCoLaus study (Preisig et al., 2009), a psychiatric 
study conducted in a population-based sample (CoLaus) (Firmann et al., 2008). First, the CoLaus study, 
based on a sample of 6,734 individuals randomly selected from the population registry of 35-75 year-old 
residents of the city of Lausanne, Switzerland, involved a comprehensive assessment of cardiovascular risk 
factors and collected DNA and plasma samples for the study of genetic variants and biomarkers. Participation 
in the CoLaus study was 43% (Firmann et al., 2008). Second, all 35 to 66-year old subjects of the CoLaus 
sample (n=5,535) were invited to participate in the psychiatric study, from which 67% accepted (n=3,720) 
(Preisig et al., 2009). Ninety-two percent of them were Caucasians. The gender distribution of the PsyCoLaus 
sample (47.1% males) did not differ from that of the source population in the same age range. Although the 
youngest 5-year band of the cohort was underrepresented and the oldest 5-year band overrepresented (mean 
age for the overall sample 50.9; s.d. 8.8 years), participants of PsyCoLaus and subjects who refused to 
participate revealed comparable scores on the General Health Questionnaire (GHQ-12: (Goldberg, 1972), a 
self-rating instrument completed at the somatic exam. 
 
The Institutional Ethics Committee of the University of Lausanne approved the CoLaus and subsequently the 
PsyCoLaus study. All participants signed a written informed consent after having received a detailed 
description of the goal and funding of the study. 
 
2.2. Measures 
Information on psychiatric disorders was collected using the French translation (Leboyer et al., 1995) of the 
semi-structured Diagnostic Interview for Genetic Studies (DIGS: (Nurnberger et al., 1994; Preisig et al., 
1999)). Interviewers were required to be masters-level psychologists, and were trained over a one- to two-
month period. During data collection, each interview was reviewed by an experienced senior clinical 
psychologist. The DIGS interview systematically assesses the last and the most severe depressive episodes. 
In addition, dysthymic episodes are assessed in a separate section. For each episode the timing and duration 
are elicited, which makes it possible to identify chronic episodes and the temporal sequence between MDEs 
and dysthymic episodes. Moreover, in order to also assess syndromes below the diagnostic threshold of MDD 
and dysthymic disorder the screening question for MDE of our French version of the DIGS did not include the 
requirement of one-week duration of the enumerated depressive symptoms as it is stipulated in the original 
English version of the DIGS. Our DIGS version revealed excellent inter-rater reliability in terms of kappa and 
Yule's Y coefficients for major psychiatric (Preisig et al., 1999) and substance use disorders (Berney et al., 
2002), whereas the 6-week test-retest reliability was lower but still acceptable (Berney et al., 2002; Preisig et 
al., 1999). Moreover, the inter-rater reliability for minor depression (Yule=0.91) and minor manic syndromes 
(Yule=0.89) was high. For the assessment of posttraumatic stress disorder (PTSD) and generalized anxiety 
disorder (GAD) the DIGS was completed with the sections of the French version (Leboyer et al., 1991) of the 
Schedule for Affective Disorders and Schizophrenia - Lifetime and Anxiety disorder version (SADS-LA) 
(Endicott and Spitzer, 1978). In addition, the brief phobia chapter of the DIGS was replaced by the 
corresponding more extensive chapters of the SADS-LA which elicit information related to agoraphobia with or 
without panic attacks, social and specific phobias. The French version of the anxiety sections of the SADS-LA 
revealed excellent inter-rater and fair to good test-retest reliability (Leboyer et al., 1991), whereas in our own 
reliability study we documented perfect inter-rater agreement for all specific anxiety disorders except for 
agoraphobia (Yule's Y = 0.96) and fair to good 6-week test-retest reliability for all anxiety disorders 
(Rougemont-Buecking et al., 2008).  
 
Diagnostic assignment was performed according to the new DSM-5 criteria for depressive disorders. Subjects 
with any form of bipolar disorder including the new category of Other Specified Bipolar and Related Disorders 
were removed from the depressive disorder groups. Regarding the assignment of PDD diagnoses, we coded 
a pure dysthymic syndrome as long as there was no occurrence of MDE within a 2-year dysthymic period, 
regardless of the occurrence of MDE at periods over lifetime. Subjects with a pure dysthymic episode and 
MDE in other periods over lifetime were coded twice, i.e. as having a pure dysthymic episode and MDD 
(n=21). In contrast, subjects meeting criteria for PDD with a persistent MDE or PDD with intermittent MDE 
were only coded in these categories. 
 
Furthermore, the DIGS comprises questions on lifetime treatment in a general section on psychopathology as 
well as more specifically within the depression section. The DIGS also collects data on a series of socio-
demographic factors. Socio-economic status (SES) was defined according to the Hollingshead scale 
(Hollingshead, 1975). The Global Assessment of Functioning (GAF) scores, which were assigned according 
to the definitions in the DSM-IV manual, provide an assessment of the subjects’ level of psychological, social 
and occupational functioning and were coded by the interviewers according to the subject's functioning over 
lifetime; i.e. the rating took into account the severity and the duration of all psychiatric symptoms that affected 
the subject's functioning over the lifespan. 
 
 
2.3. Statistical method 
Diagnostic subgroups defined according to the occurrence of depressive disorder subtypes over lifetime were 
compared on socio-demographic, course and treatment characteristics as well as the lifetime prevalence of 
comorbid disorders. Socio-demographic characteristics included sex, age, SES, low education (having 
attended compulsory school only), low income (receiving less than 50 000.- CHF per year) and benefitting 
from a disability pension. Course characteristics included age of onset, being in a current episode, number of 
suicide attempts and social functioning (lifetime, worst and current GAF scores). Treatment variables included 
consulting with a mental health specialist over lifetime, ever having taken psychotropic medication or ever 
having been hospitalized in a psychiatric setting. Multiple linear and logistic regression models were computed 
to assess associations between diagnoses and continuous or dichotomous variables, respectively. The 
models, which were adjusted for the effects of age, sex and SES, assessed the effect of the subject’s lifetime 
depressive disorder diagnosis on the outcome compared to a reference group of subjects with no lifetime 
history of depressive disorders. No adjustment for age and sex, respectively, was made when examining 
associations with age and sex. Comparisons involving age at onset and being in a current episode were 
restricted to subjects with depressive disorders. Comparisons across depressive subgroups were made 
between subgroups taken two by two using logistic regression models until all the combinations had been 
assessed. Statistical analyses were performed using the Statistical Analysis System, version 9.3 (SAS 
Institute, Inc., Cary, NC, USA). 
 
3. Results 
3.1. Lifetime prevalence of depressive spectrum disorders 
Table 1 shows the lifetime prevalence estimates for all diagnostic subgroups for the overall sample and 
according to gender. Within the overall sample, a proportion of 54.4% met criteria for any DSM-5 depressive 
disorder. This proportion is slightly lower than the sum of all prevalence estimates for the specific depression 
disorders given that subjects meeting criteria for dysthymic episode and MDE(s) that occurred before or after 
the dythymic episode were counted twice, i.e. as PPD with pure dysthymia and MDD. Within the category of 
PDD, the prevalence of PDD with intermittent MDE was very low (0.4%). For this reason this diagnostic entity 
could not be used in further analyses. Furthermore, given the low prevalence of recurrent brief depression 
(0.5%) and brief episode(s) (0.1%) in our sample the diagnoses within the OSDD category were analyzed as 
a whole. 
 
INSERT TABLE 1 HERE 
 3.2. Socio-demographic characteristics by depressive disorder status 
Socio-demographic characteristics of the sample according to depressive disorder subtypes are provided in 
Table 2. With proportions of above 57%, subjects with depressive disorders were more likely to be female 
than subjects with no depressive disorder. Within the depression subgroups, subjects with PDD with 
persistent MDE and those with recurrent MDD were more likely to be female than subjects with both single 
episode MDD and OSDD. Regarding age at interview, subjects with recurrent and single episode MDD were 
slightly younger than subjects with PDD with persistent MDE as well as compared to those with no depressive 
disorder. Moreover, subjects with single episode MDD were slightly younger than those with OSDD. 
Regarding SES according to the Hollingshead scale, subjects with PDD with pure dysthymia, recurrent MDD 
and OSDD had significantly higher SES than subjects without depressive disorders, whereas subjects with 
PDD with persistent MDE had lower SES than the other depressive subjects (excepting single MDD), 
although they did not differ from controls. Moreover, subjects with single episode MDD had lower SES than 
those with recurrent MDD. Subjects with recurrent MDD were less likely to have compulsory school education 
only than those who had never had a depressive disorder, but they did not differ from any other depressive 
subgroup regarding education level. Furthermore, subjects with PDD with persistent MDE were more likely to 
be part of the lowest income group than the subjects in all the other diagnostic groupings. Similarly, subjects 
with PDD with persistent MDE were also more likely to receive a disability pension than subjects with single 
MDD, OSDD and those who had never had a depressive disorder. The recurrent MDD group received a 
disability pension more frequently than subjects with single episode MDD, OSDD or those who had never had 
a depressive disorder. 
 
INSERT TABLE 2 HERE 
 
 
3.3. Lifetime comorbidity 
PDD with persistent MDE revealed significant associations with all lifetime anxiety disorders except for 
agoraphobia, alcohol dependence, illicit drug abuse and attention deficit hyperactivity disorder (ADHD) (Table 
3). Subjects with PDD with persistent MDE reported several of these disorders more frequently than subjects 
with single episode MDD or OSDD. Next, recurrent and single episode MDD were both associated with social 
phobia, posttraumatic stress disorder (PTSD) and illicit drug abuse, whereas recurrent MDD showed 
additional associations with generalized anxiety disorder (GAD) and obsessive compulsive disorder (OCD). 
Associations with social phobia and OCD were higher among subjects with recurrent compared to single 
episode MDD. Subjects with recurrent MDD also revealed a higher likelihood of reporting social phobia, PTSD 
and illicit drug abuse than depressive subjects with OSDD, whereas subjects with single episode MDD 
reported more PTSD, alcohol and illicit drug abuse than subjects with OSDD. Finally, subjects with PDD with 
pure dysthymia and those with OSDD did not differ from those who had never experienced a depressive 
disorder with respect to the prevalence of any assessed disorder.  
 
INSERT TABLE 3 HERE 
 
  
3.4. Clinical, course and treatment characteristics 
Comparison across the depressive subgroups revealed the earliest age of onset in subjects with recurrent 
MDD, which differed significantly from those of all other depressive groups (Table 4). Subjects with PDD with 
persistent MDE had the second lowest age of onset, which also differed from all other groups. The highest 
age of onset was observed in subjects with single episode MDD. Their age of onset was significantly later 
than that of all other depressive subjects. Subjects with PDD with persistent MDE were more likely to be in a 
current episode than all the other depressive subjects. Furthermore, subjects with PDD with pure dysthymia 
and recurrent MDD were more likely to be in a current episode than those with single episode MDD and 
OSDD. Next, subjects with PDD with persistent MDE and those with recurrent MDD were more likely to report 
suicidal attempts than subjects without a lifetime depressive disorder or subjects with other depressive 
diagnoses, except for PDD with pure dysthymia. The latter group also reported more suicide attempts than the 
group with OSDD. Regarding the GAF scores, all diagnostic groups revealed significantly lower scores than 
subjects without depressive disorders. Subjects with PDD with persistent MDE along with those with recurrent 
MDD had the lowest scores of all, and these two groups differed from each other only regarding current GAF 
scores. However, subjects with recurrent MDD did not differ from those with PDD with pure dysthymia for 
current functioning. Subjects with OSDD showed better global functioning than the subjects of all the other 
depressive categories. Association patterns similar to those of the GAF scores were observed regarding the 
treatment variables. The subjects of all depression groups were more likely to seek any professional help or 
having taken any psychotropic medication. Treatment seeking or medication was most common among 
subjects with PDD with persistent MDE, followed by those with recurrent MDD, single episode MDD, PDD with 
pure dysthymia and OSDD. Subjects with PDD with persistent MDE as well as those with recurrent MDD were 
more frequently hospitalized than those with other depressive syndromes or subjects with no history of 
depressive disorders. However, subjects with PDD with persistent MDE were not more frequently hospitalized 
than those with PDD with pure dysthymia. Finally, subjects with single MDD were more frequently hospitalized 
than those with no history of depressive disorders.  
 
INSERT TABLE 4 HERE 
 
 
4. Discussion 
Using semi-structured diagnostic interviews conducted by masters-level psychologists, the present study was, 
to our knowledge, the first to assess the prevalence and clinical significance of the wider array of depressive 
disorders according to the DSM-5 in a large random community sample. 
 
4.1. Prevalence 
With a proportion of 54.4% of the sample who met criteria for any DSM-5 depressive disorder we established 
an overall lifetime prevalence that exceeded the 44.4% measured in the population-based Zurich cohort 
study, which however was based on six interview waves conducted over a 20 year period (Angst et al., 2009). 
The Zurich study, which was also based on a semi-structured interview (Structured Psychopathological 
Interview and Rating of Social Consequences for Epidemiology), assessed disorders over the previous 12 
months for each wave, whereas our study assessed disorders over lifetime. 
 Regarding specific depressive disorders, we found a high prevalence 15.2% for the new DSM-5 category of 
PDD with persistent MDE. Previous community studies have hardly established the prevalence of this 
disorder given that they generally did not distinguish between MDD with and without episodes exceeding a 
two-year duration. However, the Zurich study documented a much lower cumulative incidence of only 5.7% for 
long-term depressive disorders (Angst et al., 2009). Given that it is difficult to distinguish between chronic 
MDE, PPD with intermittent MDE and recurrent MDD with incomplete remission using retrospectively 
assessed data over a long life span our estimate of the prevalence of PDD with persistent MDE may be 
inflated. This would also explain our very low prevalence of PPD with intermittent MDE. Following-up a clinical 
sample of subjects with MDD, Judd (Judd, 2012) reported a surprisingly substantial proportion of chronicity 
among subjects with MDD based on time spent in episodes or in subsyndromal inter-episodic periods, 
suggesting that MDD with long-lasting or incompletely remitting episodes are common in clinical settings. 
However, prospective cohort studies conducted in the community are necessary to further test whether this is 
also true in the general population.  
Our lifetime prevalence of 28.2% for MDD also lies above the typical range of lifetime estimates according to 
recent studies based on DSM-IV criteria, including the NCS-R study (16.2%; (Merikangas et al., 2007), the 
World Mental Health Survey Initiative (14.6% in high-income countries; 21% in France and 19.2% in the US; 
(Bromet et al., 2011)) as well as the NEMESIS study in the Netherlands which relied on DSM-III-R criteria 
(15.4%; (Bijl et al., 1998)). With a cumulative incidence of 32.5% for DSM-IV MDD only the latest analysis of 
the Zurich study cohort study revealed rates similar to ours (Angst et al., 2016).  
Our high prevalence for PDD with MDE and MDD could at least partially be explained by the particular 
features of our sample and our diagnostic instrument. Indeed, our sample was recruited in an urban area and 
there is evidence for high prevalence of any psychiatric disorder including depressive disorders in urban areas 
(e.g. NEMESIS) (Peen et al., 2007). In addition, the characteristics of our DIGS interview further favored the 
establishment of high prevalence estimates for depressive disorders. First, in order to assess disorders below 
the diagnostic threshold of MDD we applied a low threshold with no minimum time requirement in the 
screening questions to enter the depression section. Accordingly, the large majority (63%) of participants of 
our study entered the depression section which increased the likelihood of the assignment of depression 
diagnoses. Second, the semi-structured nature of the DIGS was likely to provide higher prevalence estimates 
than the fully structured Composite International Diagnostic Interview (CIDI), which was applied in most 
previous community surveys. Indeed, research that compared the fully structured Diagnostic Interview 
Schedule (DIS), designed similarly to the CIDI for lay interviewers, with the semi-structured Schedule for 
Clinical Assessment in Neuropsychiatry (SCAN) found twice as high rates of MDD according to the latter 
interview conducted by mental health professionals (Eaton et al., 2000). It has been suggested that structured 
interviews may under-estimate the prevalence of MDD in community samples (Kruijshaar et al., 2005). The 
fact that 70% of the subjects meeting criteria for any depressive disorder reported having sought medical help 
for these conditions supports the validity of our depression diagnoses. Nevertheless our prevalence of PDD 
with persistent MDE is intriguingly high and we cannot exclude that subjects with chronic forms of depression 
were more prone to participate in the time-consuming physical and psychiatric assessments of the present 
study. 
 
In contrast to PDD with persistent MDE and MDD, our lifetime prevalence estimates for PDD with pure 
dysthymia and OSDD were comparable to those of previous research. Our estimate of 2.5% for PDD with 
pure dysthymia was in the same range as those reported in several community-based studies relying on the 
CIDI and DSM-IV definition (range: 0.1 to 2.7%; review (Gureje, 2011)). Considering OSDD, we established a 
lifetime prevalence of 9.1% for OSDD, which mostly involved the diagnosis of Depressive episode(s) with 
insufficient symptoms. The prevalence 8.5% for the latter diagnosis is close to the 9.9% of the similarly 
defined minor depression diagnosis in the Zurich Cohort Study (Angst et al., 2003). Using a wide variety of 
definitions and measures other cross-sectional studies reported lower prevalence estimates for minor 
depression ranging from 2.8 to 6.1% (Rodriguez et al., 2012). In contrast, our rates of only 0.5% for Recurrent 
brief depression and 0.1% for Short-duration depressive episodes were much lower than those of the Zurich 
Cohort Study (4.0% and 5.1%, respectively) (Angst et al., 2014a). It is possible that the prospective design 
with 6 assessments and the more thorough probing for depressive symptoms (28 depressive symptoms listed 
in the case of a positive response to the screen of ‘loss of joy and energy’ or ‘low mood’) favored recall of brief 
episodes in the Zurich Cohort Study. 
 
4.1. Clinical correlates of depressive spectrum disorders 
Our study revealed the highest disorder severity in subjects with PDD with persistent MDE, followed by those 
with recurrent MDD, single episode MDD and both PDD with pure dysthymia and the OSDD category. 
However, our data provided support for the clinical relevance of all depressive disorders as defined in the 
DSM-5 with notably significant lower social functioning as measured by the GAF score and higher rates of 
treatment seeking of all diagnostic groups including the new OSDD category. Our observation of the highest 
disorder severity of subjects with PDD with persistent MDE is not surprising. With the exception of recurrent 
MDD, this diagnostic group significantly differed from all other DSM-5 depressive disorders in terms of socio-
demographic characteristics, comorbidity patterns and course, whereas PDD with persistent MDE and 
recurrent MDD only differed regarding SES, income, age of onset, likelihood of being in a current episode and 
current GAF scores. In turn, subjects with single episode MDD were less severely impaired in terms of 
comorbid disorders, suicide attempts, social functioning and treatment seeking. This is in line with two clinical 
studies that revealed lower symptom severity (Hollon et al., 2006) and suicidal risk (Witte et al., 2009) in 
single episode as compared to recurrent MDD, whereas one community study did not find the two MDD 
subtypes to differ regarding impairment (Kruijshaar et al., 2003). Regarding PDD with pure dysthymia, our 
data revealed a significantly lower severity of this disorder regarding most socio-demographic, course and 
treatment characteristics than both PDD with persistent MDE and recurrent MDD. PDD with pure dysthymia 
occupied an intermediate position between single episode MDD and OSDD and hardly differed from either of 
the two regarding socio-demographics and comorbidity, whereas subjects with OSDD were the least severely 
affected and differed from subjects with single episode MDD regarding some comorbidity patterns and most 
course and treatment variables. Nevertheless subjects with OSDD still showed a significantly poorer 
psychosocial functioning and a higher use of psychiatric treatment services and psychotropic medication than 
subjects with no history of depressive disorders providing additional support for the clinical relevance of these 
mild depressive categories, which is consistent with strong previous evidence from the Zurich Cohort Study 
(Angst et al., 2014b), but also other community studies (Cuijpers and Smit, 2008; Howland et al., 2008; Judd 
et al., 2002; Kruijshaar et al., 2003; Meeks et al., 2011; Rodriguez et al., 2012). Therefore, although the 
disorders of the newly defined OSDD category reveal a lower degree of severity than MDD, they require 
thorough clinical attention. 
 
Given the considerable gap between PDD with persistent MDE and PDD with pure dysthymia regarding a 
large array of severity indicators according to our community data, grouping these disorders together as 
proposed by the DSM-5 entails the risk of having created a broad, heterogeneous diagnostic category with 
differing conditions and the necessity for potentially different clinical interventions (Rhebergen and Graham, 
2013). PDD with persistent MDE was much more similar to recurrent MDD than to PDD with pure dysthymia, 
which challenges the separation of the former category from MDD. Conversely, PDD with pure dysthymia 
revealed more similarity with the disorders of the OSDD category. Although borders between diagnostic 
groups that represent a gradient rather than distinct entities are artificial and difficult to validate, our data 
suggest that splitting depressive disorders into a more severe MDD and a less severe OSDD category 
including dysthymia, together with a re-actualization of the DSM-IV chronicity specifier applicable to episodes 
exceeding a two-year duration in both diagnostic categories, might be more parsimonious and more adequate 
for classifying depressive disorders than the approach proposed by the DSM-5. However, before more 
definitive conclusions can be drawn regarding the pertinence of the DSM-5 classification of depressive 
disorders our results need to be replicated by other studies using the DSM-5 definitions. 
 
4.3. Limitations 
The results of the present study should also be placed in the context of several limitations. First, given the low 
participation rate, our findings with respect to prevalence estimates in particular need to be considered with 
caution. Comparisons with the sex and age-distribution of the general population of the city of Lausanne 
revealed that younger age groups are underrepresented. As depressive disorders are typically more prevalent 
in these age groups than in older age groups (Bromet et al., 2011), the undersampling of younger subjects is 
likely to have had a deflating effect on our prevalence estimates. Moreover, as already mentioned comparison 
with other surveys conducted in the community suggests that subjects with chronic MDD may have been 
more prone to participate in our study. Regarding the impact of potential selection bias on the magnitude of 
the assessed associations between depression spectrum disorders and socio-demographic or clinical 
variables, speculations on the direction of the effect of this potential bias are hardly feasible. The second 
limitation is that, owing to the rareness of PDD with intermittent MDE and brief depressive episodes in our 
sample, we could not conduct analyses using these specific subgroups. Third, the restriction of the sample to 
the age range from 35 to 66 years reduced the generalizability of our findings. Indeed, the observed 
associations may not apply to populations of subjects younger than 35 years or populations of subjects older 
than 66 years. Fourth, our assessment of the DSM-5 depressive disorders was not complete as we had no 
pertinent information to assign the diagnosis of premenstrual dysphoric disorder. Fifth, the cross-sectional 
study design may have entailed inaccurate recall of remote depressive symptoms. Hence, episodes with mild 
depressive symptoms in particular could have been under-reported leading to an underestimation of their 
prevalence. However, given that our estimates for mild depressive disorders were similar to that of the Zurich 
Cohort Study with 6 assessments, it is unlikely that incomplete recall considerably biased our estimates for 
these disorders. 
 
4.4. Conclusion 
Using the new DSM-5 definitions for depressive disorders, our findings revealed a severity gradient from the 
most severe chronic or recurrent to mild depressive disorders, which is compatible with the concept of a 
depression spectrum (Angst et al., 2000; Lewinsohn et al., 2000). However our data also show the two most 
severe depressive disorders, PDD with persistent MDE and recurrent MDD, to differ from the other depressive 
disorders regarding most clinical, course and treatment characteristics, supporting the distinction of a more 
severe from a milder group of depressive disorders. Our results only provide partial evidence for the 
pertinence of the new grouping of depressive disorders according to the DSM-5. Corroborating findings of a 
series of previous studies (Angst et al., 2014a; Cuijpers and Smit, 2008; Howland et al., 2008; Judd et al., 
2002; Kruijshaar et al., 2003; Meeks et al., 2011; Rodriguez et al., 2012), the established clinical relevance of 
the mild depressive disorders within OSDD in the present study supports the introduction of this new category 
in the DSM-5. In contrast, our results cast doubt on the pertinence of the new PDD category in the DSM-5 
given that lumping together the former DSM-IV dysthymic disorder and MDD with persistent MDE is likely to 
result in a heterogeneous diagnostic group of disorders. 
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Table 1: Lifetime prevalence of DSM-5 depressive disorders in all subjects and by gender 
 
 
 
  
 
Depression Spectrum Disorder 
All 
n=3’720 
% (n) 
95% CI 
Males 
n=1750 
% (n) 
95% CI 
Females 
n=1970 
% (n) 
95% CI 
Any Persistent Depressive Disorder (PDD) 18.0 (670) 
16.8 - 19.2 
12.5 (218) 
10.9 – 14.0 
22.9 (452) 
21.1 – 24.8 
Persistent Depressive Disorder with persistent MDE 15.2 (565) 
14.1 - 16.4 
10.2 (179) 
8.8 – 11.7 
19.6 (386) 
17.9 – 21.4 
Persistent Depressive Disorder with intermittent MDE 0.4 (13) 
0.2 - 0.5 
0.3 (6) 
0.1 – 0.6 
0.4 (7) 
0.0 – 0.6 
Persistent Depressive Disorder with pure Dysthymic syndrome 2.5 (92) 
2.0 – 3.0 
1.9 (33) 
1.3 – 2.5 
3.0 (59) 
2.2 – 3.8 
Any MDD
1
 28.0 (1’037) 
26.5 – 29.4 
21.5 (375) 
19.6 – 23.4 
33.7 (662) 
31.6 – 35.8 
MDD with recurrent episodes
1
 10.6 (391) 
10.0 – 11.5 
6.9 (121) 
5.7 – 8.1 
13.8 (270) 
12.2 – 15.3 
MDD, single episode
1
 17.4 (646) 
16.2 – 18.6 
14.6 (254) 
12.9 – 16.2 
20.0 (392) 
18.2 – 21.7 
Any Other Specified Depressive Disorder (OSDD) 9.1 (337) 
8.2 – 10.0 
8.2 (144) 
7.0 – 9.5 
9.8 (193) 
8.5 – 11.1 
Depressive episode with insufficient symptoms 8.5 (315) 
7.6 – 9.4 
7.9 (138) 
6.6 – 9.2 
9.0 (177) 
7.7 – 10.3 
Recurrent brief depression 0.5 (17) 
0.2 – 0.7 
0.3 (5) 
0.0 – 0.5 
0.6 (12) 
0.3 – 1.0 
Short-duration depressive episode (4-13 days) 0.1 (5) 
0.0 – 0.3 
0.1 (1) 
-0.0 – 0.2 
0.2 (4) 
0.0 – 0.4 
MDE = major depressive episode; MDD = major depressive disorder; 95% CI = 95% Confidence Intervals. 
1 
Excluding the categories of Persistent Depressive Disorder with persistent MDE and Persistent Depressive Disorder with intermittent MDE. 
 
 Table 2: Socio-demographic characteristics by diagnostic group 
 
 
 
 
  
 
PDD with persistent MDE 
(N=565) 
PDD, pure dysthymia
1
 
(N=92) 
MDD recurrent
2
 
(N=391) 
MDD single
2
 
(N=646) 
OSDD 
(N=337) 
Others 
(ref) 
(N=1’697) 
Comparisons 
across 
depression 
subtypes § 
Socio-demographic 
characteristics 
% or mean
b
 
OR
a
/β
a,b
 
(95%C.I.) 
% or mean
b
 
OR
a
/β
a,b
 
(95%C.I.) 
% or mean
b
 
OR
a
/β
a,b
 
(95%C.I.) 
% or mean
b
 
OR
a
/β
a,b
 
(95%C.I.) 
% or mean
b
 
OR
a
/β
a,b
 
(95%C.I.) 
% or mean
b
 
Significant  
differences
a
 
Sex, (female) % 68.3 
3.2*** 
(2.6,4.0) 
64.1 
2.2*** 
(1.4,3.4) 
69.1 
3.3*** 
(2.6,4.2) 
60.7 
2.3*** 
(1.9,2.7) 
57.3 
2.0*** 
(1.6,2.5) 
40.1  C D H I  
Age, mean (s.d.) 51.5 (8.8) 
-0.1  
(-0.9,0.8) 
50.9 (8.5) 
-0.2  
(-2.0,1.6) 
50.0 (8.2) 
-1.5**  
(-2.5, -0.5) 
49.5 (8.7) 
-2.0***  
(-2.8,-1.2) 
50.7 (8.9) 
-0.8  
(-1.8,0.2) 
51.5 (8.8) B C J 
SES, mean (s.d.)
c
 3.2 (1.3) 
-0.1  
(-0.2,0.1) 
3.6 (1.3) 
0.3*  
(0.1,0.5) 
3.6 (1.3) 
0.3***  
(0.2,0.5) 
3.4 (1.3) 
0.1 
(-0.1,0.2) 
3.5 (1.3) 
0.2*  
(0.1,0.3) 
3.3 (1.3) A B D H  
Low education, % 
(Compulsory school only) 
12.2 
0.9 
 (0.7,1.2) 
8.7 
0.7  
(0.3,1.4) 
9.2 
0.7*  
(0.5,1.0) 
10.3 
0.8  
(0.6,1.0) 
11.3 
0.8  
(0.6,1.2) 
12.8 - 
Low income, %  
(<50’000 CHF per year) 
33.2 
2.0*** 
(1.6,2.5) 
20.2 
1.0  
(0.6,1.7) 
23.4 
1.3  
(1.0,1.7) 
21.9 
1.2  
(1.0,1.5) 
22.6 
1.3  
(0.9,1.7) 
18.3  A B C D  
Disability Pension, % 9.8 
3.2*** 
(2.2,4.7) 
6.6 
2.0 
(0.8,4.7) 
5.9 
1.9**  
(1.2,3.2) 
3.3 
1.0  
(0.6,1.7) 
3.0 
0.9  
(0.5,1.8) 
3.6 C D H I  
PDD = persistent depressive disorder; MDE = major depressive episode; MDD = major depressive disorder; OSDD = other specified depressive disorders; SES = socio-economic status;  
ref = reference category; s.d.: standard deviation; OR = odd’s ratios; 95%C.I: 95% confidence interval; CHF: Swiss francs. 
1 
An MDE may occur over lifetime but not simultaneously to the PDD; 
 
2 
Excluding the categories of
 
PDD with persistent MDE and PDD with intermittent MDE; 
a 
adjusted for age and sex (except for the analyses including sex and age as the dependant variable); 
b 
mean and β-estimators in italics; 
c 
SES according to the Hollingshead scale. 
***p<0.001; **p<0.01;*p<0.05. 
§ A = PDD with persistent MDE vs. PDD, pure dysthymia; B = PDD with persistent MDE vs. MDD recurrent; C = PDD with persistent MDE vs. MDD single; D = PDD with persistent MDE vs.  
OSDD; E = PDD, pure dysthymia vs. MDD recurrent; F= PDD, pure dysthymia vs. MDD single; G = PDD, pure dysthymia vs. OSDD; H = MDD recurrent vs. MDD single; I = MDD recurrent 
vs. OSDD; J = MDD single vs. OSDD. 
 Table 3: Lifetime comorbidity of DSM-5 depressive disorders with other DSM-IV psychiatric disorders 
 
 
 
   
 
PDD with persistent MDE 
(N=565) 
PDD, pure dysthymia
1
 
(N=92) 
MDD recurrent
2
 
(N=391) 
MDD single
2
 
(N=646) 
OSDD 
(N=337) 
Others 
(ref) 
(N=1’697) 
Comparisons 
across 
depression 
subtypes § 
Comorbid disorders % OR (95%C.I.)
a
 % OR (95%C.I.)
a
 % OR (95%C.I.)
a
 % OR (95%C.I.)
a
 % OR (95%C.I.)
a
 % 
Significant  
differences
a
 
Agoraphobia 5.0 1.5 (0.9,2.5) 6.5 1.9 (0.8,4.5) 5.4 1.7 (1.0,2.9) 4.7 1.5 (0.9,2.4) 3.6 1.2 (0.6,2.3) 2.6 - 
Social Phobia 21.0 2.6*** (2.0,3.4) 13.0 1.3 (0.7,2.4) 20.7 2.6*** (1.9,3.5) 12.6 1.4* (1.0,1.9) 8.3 0.9 (0.6,1.4) 8.6 C D H I 
Generalized Anxiety Disorder 5.5 3.9*** (2.2,6.9) 3.3 2.2 (0.6,7.3) 3.1 2.3* (1.1,4.8) 1.7 1.2 (0.6,2.6) 1.5 1.1 (0.4,2.9) 1.5 C D 
Panic disorder 5.8 2.0** (1.3,3.3) 4.4 1.6 (0.6,4.4) 3.8 1.3 (0.7,2.5) 2.9 1.1 (0.6,1.8) 2.7 1.0 (0.5,2.1) 2.2 C 
Post-traumatic Stress Disorder 9.8 4.6*** (2.9,7.2) 4.4 1.6 (0.6,4.5) 6.5 3.0*** (1.8,5.2) 4.0 1.8* (1.1,3.1) 1.2 0.6 (0.2,1.6) 2.0 C D J I 
OCD 2.7 3.1** (1.5,6.3) 0 - 2.6 2.8* (1.3,6.4) 0.8 0.8 (0.3,2.3) 0 - 1.0 C H 
Alcohol abuse 9.1 1.3 (0.9,1.9) 8.7 1.2 (0.5,2.5) 8.5 1.3 (0.9,2.0) 10.3 1.3 (1.0,1.8) 6.0 0.7 (0.4,1.1) 10.7 D J 
Alcohol dependence 6.4 2.0** (1.3,3.0) 2.2 0.6 (0.1,2.6) 4.1 1.3 (0.8,2.4) 4.0 1.1 (0.7,1.8) 3.9 1.0 (0.6,1.9) 4.7 C 
Illicit drug abuse 3.3 1.8* (1.0,3.3) 4.4 1.6 (0.6,4.7) 5.6 2.8*** (1.6,5.0) 6.0 2.7*** (1.7,4.3) 2.7 1.2 (0.6,2.6) 2.6 I J 
Illicit drug dependence 3.0 1.4 (0.8,2.6) 1.1 0.5 (0.1,3.5) 3.1 1.4 (0.7,2.8) 2.3 0.9 (0.5,1.6) 2.1 0.9 (0.4,1.9) 2.8 - 
ADHD 3.7 1.8* (1.0,3.2) 2.2 1.1 (0.3,4.4) 2.9 1.5 (0.8,3.0) 2.7 1.2 (0.7,2.2) 1.2 0.4 (0.1,1.4) 2.4 D 
Disruptive Behavioral Disorder 3.9 1.0 (0.6,1.7) 1.1 0.3 (0.0,2.0) 4.2 1.0 (0.6,1.9) 4.2 1.0 (0.6,1.5) 4.2 1.0 (0.5,1.8) 4.8 - 
PDD = persistent depressive disorder; MDE = major depressive episode; MDD = major depressive disorder; OSDD = other specified depressive disorders; OR = odd’s ratios; 
95% C.I. = 95 % confidence intervals; ref = reference category; OCD = Obsessive Compulsive Disorder; ADHD = Attention Deficit/ Hyperactivity Disorder. 
1 
An MDE may occur over lifetime but not simultaneously to the PDD; 
 
2 
Excluding the categories of
 
PDD with persistent MDE and PDD with intermittent MDE; 
a
 adjusted for age, sex and socio-economic status.      ***p<0.001; **p<0.01;*p<0.05. 
 
§ A = PDD with persistent MDE vs. PDD, pure dysthymia; B = PDD with persistent MDE vs. MDD recurrent; C = PDD with persistent MDE vs. MDD single; D = PDD with 
persistent MDE vs.  OSDD; E = PDD, pure dysthymia vs. MDD recurrent; F= PDD, pure dysthymia vs. MDD single; G = PDD, pure dysthymia vs. OSDD; H = MDD recurrent vs. 
MDD single; I = MDD recurrent vs. OSDD; J = MDD single vs. OSDD. 
 Table 4: Clinical, course and treatment characteristics by diagnostic group 
 
 
PDD with persistent MDE 
(N=565) 
PDD, pure dysthymia
1
 
(N=92) 
MDD recurrent
2
 
(N=391) 
MDD single
2
 
(N=646) 
OSDD 
(N=337) 
Others 
(ref) 
(N=1’697) 
Comparisons 
across 
depression 
subtypes § 
Course and 
treatment 
% or mean
b
 
OR
a
 / β
a,b
  
(95%C.I.) 
% or 
mean
b
 
OR
a
/ β
a,b
 
(95%C.I.) 
% or 
mean
b
 
OR
a
/ β
a,b
 
(95%C.I.) 
% or 
mean
b
 
OR
a
/ β
a,b
 
(95%C.I.) 
% or 
mean
b
 
OR
a
/ β
a,b
  
(95%C.I.) 
% or  
mean
b
 
Significant  
differences
a
 
Age of onset, 
mean (s.d.) 
31.0 (13.6) -5.9*** (-7.3 ,-4.4) 33.9 (13.0) -2.0 (-4.7,0.6) 27.6 (10.7) -8.3*** (-9.8,-6.7) 38.6 (11.0) 2.8*** (1.4,4.2) 36.7 (11.1) (ref) - A B C D E F H I j
Current episode, 
% 
31.6 4.9*** (3.2.7.4) 19.6 2.6** (1.5.4.8) 17.4 2.4*** (1.5.3.7) 7.0 0.8 (0.5,1.2) 8.1 (ref) - A B C D F G H I 
Suicide attempt, 
% 
12.8 3.9*** (2.7,5.7) 7.6 1.9 (0.8,4.2) 13.5 4.5*** (3.0,6.8) 4.5 1.3 (0.8,2.1) 3.0 0.8 (0.4,1.7) 3.3 C D G H I 
GAF
 
-lifetime, 
mean (s.d.) 
68.2 (10.6) -13.3*** (-14.2 ,-12.3) 74.0 (9.9) -6.1*** (-8.1,-4.1) 69.2 (9.6) -12.5*** (-13.5,-11.4) 75.8 (8.6) -5.5*** (-6.4,-4.6) 78.9 (7.9) -2.8*** (-4.0,-1.7) 81.5 (10.3) A C D E F G H I J
GAF
 
-worst, 
mean (s.d.) 
40.8 (10.6) -24.4*** (-26.0,-23.0) 48.7 (13.0) -11.9*** (-15.1,-8.7) 40.0 (10.6) -25.2*** (-27.0,-23.5) 45.2 (10.6) -19.7*** (-21.1,-18.3) 55.1 (12.7) -10.4*** (-12.2,-8.6) 65.8 (19.5) A C D E F G H I J
GAF
 
-current, 
mean (s.d.) 
68.8 (17.3) -14.5*** (-15.7,-13.2) 75.2 (14.5) -7.0*** (-9.8,-4.2) 72.9 (16.0) -10.7*** (-12.2,-9.2) 78.1 (14.4) -5.1*** (-6.3,-3.9) 81.6 (11.3) -2.1** (-3.6,-0.5) 83.4 (11.3) A B C D F G H I J
Any treatment 
seeking, % 
82.5 13.7*** (10.7,17.6) 68.5 4.6*** (2.8,7.3) 81.3 11.9*** (9.0,15.8) 66.3 5.7*** (4.6,7.0) 49.6 2.9*** (2.3,3.7) 23.8 A C D E G H I J 
Any medication, 
% 
63.4 8.0*** (6.4,9.9) 35.9 1.7* (1.1,2.7) 66.8 9.7*** (7.5,12.5) 48.3 4.6*** (3.7,5.6) 25.2 1.6*** (1.2,2.2) 15.9 A C D E F G H I J
Any 
hospitalization, 
% 
11.9 3.5*** (2.4,5.0) 5.4 1.2 (0.5,3.2) 13.8 4.7*** (3.2,7.0) 5.4 1.6* (1.0,2.4) 3.3 0.9 (0.5,1.7) 4.0 C D E H I 
PDD = persistent depressive disorder; MDE = major depressive episode; MDD = major depressive disorder; OSDD = other specified depressive disorders;  
OR = odd’s ratios; 95% C.I. = 95 % confidence intervals; ref = reference category; s.d. = standard deviation; GAF = Global Assessment of Functioning score. 
1 
An MDE may occur over lifetime but not simultaneously to the PDD; 
 
2 
Excluding the categories of
 
PDD with persistent MDE and PDD with intermittent MDE; 
a 
adjusted for age, sex and socio-economic status;  
b 
mean and β-estimators in italics; 
***p<0.001; **p<0.01;*p<0.05. 
§ A = PDD with persistent MDE vs. PDD, pure dysthymia; B = PDD with persistent MDE vs. MDD recurrent; C = PDD with persistent MDE vs. MDD single; D = 
PDD with persistent MDE vs.  OSDD; E = PDD, pure dysthymia vs. MDD recurrent; F= PDD, pure dysthymia vs. MDD single; G = PDD, pure dysthymia vs. 
OSDD; H = MDD recurrent vs. MDD single; I = MDD recurrent vs. OSDD; J = MDD single vs. OSDD. 
